Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology
2024; Elsevier BV; Volume: 16; Issue: 2 Linguagem: Inglês
10.1002/dad2.12589
ISSN2352-8729
AutoresLara Blömeke, Fabian Rehn, Victoria Kraemer‐Schulien, Janine Kutzsche, Marlene Pils, Tuyen Bujnicki, Piotr Lewczuk, Johannes Kornhuber, Silka Dawn Freiesleben, Luisa‐Sophie Schneider, Lukas Preis, Josef Priller, Eike Jakob Spruth, Slawek Altenstein, Andrea Lohse, Anja Schneider, Klaus Fließbach, Jens Wiltfang, Niels Hansen, Ayda Rostamzadeh, Emrah Düzel, Wenzel Glanz, Enise I. Incesoy, Michaela Butryn, Katharina Büerger, Daniel Janowitz, Michael Ewers, Robert Perneczky, Boris‐Stephan Rauchmann, Stefan Teipel, Ingo Kilimann, Doreen Göerß, Christoph Laske, Matthias H. Munk, Carolin Sanzenbacher, Annika Spottke, Nina Roy‐Kluth, Michael T. Heneka, Frederic Brosseron, Michael Wagner, Steffen Wolfsgruber, Luca Kleineidam, Melina Stark, Matthias Schmid, Frank Jessen, Oliver Bannach, Dieter Willbold, Oliver Peters,
Tópico(s)Cholinesterase and Neurodegenerative Diseases
ResumoSoluble amyloid beta (Aβ) oligomers have been suggested as initiating Aβ related neuropathologic change in Alzheimer's disease (AD) but their quantitative distribution and chronological sequence within the AD continuum remain unclear.
Referência(s)